ARASENS: Darolutamide for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ARASENS: Darolutamide for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

AnnualMeeting2017

2 years
1,092 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Up Next Autoplay